NCT01362348View on ClinicalTrials.gov

12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 7, 2011

Primary Completion Date

April 16, 2012

Study Completion Date

April 16, 2012

Conditions
Macular Degeneration
Interventions
DRUG

pazopanib eye drops

10 mg/mL (1 drop) four times daily

Trial Locations (15)

30030

GSK Investigational Site, Decatur

33143

GSK Investigational Site, Miami

33880

GSK Investigational Site, Winter Haven

44195

GSK Investigational Site, Cleveland

48145

GSK Investigational Site, Münster

49525

GSK Investigational Site, Grand Rapids

53127

GSK Investigational Site, Bonn

75475

GSK Investigational Site, Paris

75571

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

78705

GSK Investigational Site, Austin

80336

GSK Investigational Site, Munich

85014

GSK Investigational Site, Phoenix

02114

GSK Investigational Site, Boston

04103

GSK Investigational Site, Leipzig

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01362348 - 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter